Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 10, 2011, Pages 630-637

  Aubert, J ^a   Begriche, K ^a   Knockaert, L ^a   Robin, M A ^a   Fromenty, B ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ADIPONECTIN; CYTOCHROME P450 2E1; INSULIN; LEPTIN; MESSENGER RNA; OLEIC ACID; PALMITIC ACID; PARACETAMOL; REACTIVE OXYGEN METABOLITE;

CELL PERMEABILIZATION; CELL VIABILITY; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TRANSFORMATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME STABILITY; HUMAN; HYPERLEPTINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPID STORAGE; LIVER INJURY; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SHORT SURVEY; STEATOSIS;

CYTOCHROME P-450 CYP2E1; FATTY LIVER; HUMANS;

EID: 80054859494     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.04.015     Document Type: Short Survey

References (83)

1. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37:1202-1209.
2. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6:1-28.
3. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-S112.
4. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
5. Wieckowska A., McCullough A.J., Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46:582-589.
6. Cave M., Deaciuc I., Mendez C., Song Z., Joshi-Barve S., Barve S., et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007, 18:184-195.
7. Postic C., Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008, 34(6 Pt 2):643-648.
8. Begriche K., Knockaert L., Massart J., Robin M.A., Fromenty B. Mitochondrial dysfunction in nonalcoholic steatohepatitis (NASH): are there drugs able to improve it?. Drug Discov Today 2009, 6:e11-e23.
9. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
10. Robertson G., Leclercq I., Farrell G.C. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1135-G1139.
11. Song B.J. Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 update. Alcohol Clin Exp Res 1996, 20:138A-146A.
12. Gonzalez F.J. Role of cytochrome P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005, 569:101-110.
13. Hinson J.A., Roberts D.W., James L.P. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol 2010, 196:369-405.
14. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008, 22:335-353.
15. Porubsky P.R., Meneely K.M., Scott E.E. Structures of human cytochrome P450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem 2008, 283:33698-33707.
16. Robin M.A., Anandatheerthavarada H.K., Fang J.K., Cudic M., Otvos L., Avadhani N.G. Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity. J Biol Chem 2001, 276:24680-24689.
17. Robin M.A., Sauvage I., Grandperret T., Descatoire V., Pessayre D., Fromenty B. Ethanol increases mitochondrial cytochrome P450 2E1 in mouse liver and rat hepatocytes. FEBS Lett 2005, 579:6895-6902.
18. Knockaert L., Descatoire V., Vadrot N., Fromenty B., Robin M.A. Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol In Vitro 2011, 25:475-484.
19. Cahill A., Cunningham C.C., Adachi M., Ishii H., Bailey S.M., Fromenty B., et al. Effects of alcohol and oxidative stress on liver pathology: the role of the mitochondrion. Alcohol Clin Exp Res 2002, 26:907-915.
20. Demeilliers C., Maisonneuve C., Grodet A., Mansouri A., Nguyen R., Tinel M., et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002, 123:1278-1290.
21. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995, 67:101-154.
22. Hardwick J.P. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 2008, 75:2263-2275.
23. Lieber C.S. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004, 36:511-529.
24. Roberts B.J., Song B.J., Soh Y., Park S.S., Shoaf S.E. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 1995, 270:29632-29635.
25. Gonzalez F.J. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 2007, 35:1-8.
26. Raucy J.L., Lasker J.M., Kraner J.C., Salazar D.E., Lieber C.S., Corcoran G.B. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991, 39:275-280.
27. Zou Y., Li J., Lu C., Wang J., Ge J., Huang Y., et al. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 2006, 79:1100-1107.
28. Khemawoot P., Yokogawa K., Shimada T., Miyamoto K. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats. Biochem Pharmacol 2007, 73:155-162.
29. Begriche K., Lettéron P., Abbey-Toby A., Vadrot N., Robin M.A., Bado A., et al. Partial leptin deficiency favours diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab 2008, 294:E939-E951.
30. Osabe M., Sugatani J., Fukuyama T., Ikushiro S., Ikari A., Miwa M. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos 2008, 36:294-302.
31. Baumgardner J.N., Shankar K., Hennings L., Badger T.M., Ronis M.J. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol 2008, 294:G27-G38.
32. Mantena S.K., Vaughn D.P., Andringa K.K., Eccleston H.B., King A.L., Abrams G.A., et al. High-fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009, 417:183-193.
33. O'Shea D., Davis S.N., Kim R.B., Wilkinson G.R. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994, 56:359-367.
34. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
35. Niemelä O., Parkkila S., Juvonen R.O., Viitala K., Gelboin H.V., Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and nonalcoholic liver diseases. J Hepatol 2000, 33:893-901.
36. Chalasani N., Gorski J.C., Asghar M.S., Asghar A., Foresman B., Hall S.D., et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003, 37:544-550.
37. Emery M.G., Fisher J.M., Chien J.Y., Kharasch E.D., Dellinger E.P., Kowdley K.V., et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003, 38:428-435.
38. Varela N.M., Quinones L.A., Orellana M., Poniachik J., Csendes A., Smok G., et al. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women. Biol Res 2008, 41:81-92.
39. Bell L.N., Temm C.J., Saxena R., Vuppalanchi R., Schauer P., Rabinovitz M., et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P450 protein content. Ann Surg 2010, 251:1041-1048.
40. Takamura T., Misu H., Matsuzawa-Nagata N., Sakurai M., Ota T., Shimizu A., et al. Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Obesity 2008, 16:2601-2609.
41. Mitsuyoshi H., Yasui K., Harano Y., Endo M., Tsuji K., Minami M., et al. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res 2009, 39:366-373.
42. Baker S.S., Baker R.D., Liu W., Nowak N.J., Zhu L. Role of alcohol metabolism in nonalcoholic steatohepatitis. PLoS One 2010, 5:e9570.
43. Matsuzawa-Nagata N., Takamura T., Ando H., Nakamura S., Kurita S., Misu H., et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 2008, 57:1071-1077.
44. Chtioui H., Semela D., Ledermann M., Zimmermann A., Dufour J.F. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int 2007, 27:764-771.
45. Raucy J.L., Lasker J., Ozaki K., Zoleta V. Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 2004, 79:233-241.
46. Anthérieu S., Rogue A., Fromenty B., Guillouzo A., Robin M.A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 2011, 10.1002/hep.24290.
47. Yun Y.P., Casazza J.P., Sohn D.H., Veech R.L., Song B.J. Pretranslational activation of cytochrome P450IIE during ketosis induced by a high-fat diet. Mol Pharmacol 1992, 41:474-479.
48. Moncion A., Truong N.T., Garrone A., Beaune P., Barouki R., De Waziers I. Identification of a 16-nucleotide sequence that mediates posttranscriptional regulation of rat CYP2E1 by insulin. J Biol Chem 2002, 277:45904-45910.
49. Woodcroft K.J., Hafner M.S., Novak R.F. Insulin signalling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 2002, 35:263-273.
50. Haeusler R.A., Accili D. The double life of Irs. Cell Metab 2008, 8:7-9.
51. Borghi V.C., Wajchenberg B.L., Cesar F.P. Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Metabolism 1984, 33:1068-1074.
52. Weiss R., D'Adamo E., Santoro N., Hershkop K., Caprio S. Basal alpha-cell up-regulation in obese insulin-resistant adolescents. J Clin Endocrinol Metab 2011, 96:91-97.
53. Woodcroft K.J., Novak R.F. The role of phosphatidylinositol 3-kinase, Src kinase, and protein kinase A signalling pathways in insulin and glucagon regulation of CYP2E1 expression. Biochem Biophys Res Commun 1999, 266:304-307.
54. Forkert P.G., Redza Z.M., Mangos S., Park S.S., Tam S.P. Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration. Drug Metab Dispos 1994, 22:248-253.
55. Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
56. Leclercq I.A., Field J., Enriquez A., Farrell G.C., Robertson G.R. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun 2000, 268:337-344.
57. Kamada Y., Matsumoto H., Tamura S., Fukushima J., Kiso S., Fukui K., et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007, 47:556-564.
58. Hakkola J., Hu Y., Ingelman-Sundberg M. Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J Pharmacol Exp Ther 2003, 304:1048-1054.
59. Wang J., Hu Y., Nekvindova J., Ingelman-Sundberg M., Neve E.P. IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signalling pathways. Biochem Pharmacol 2010, 80:1592-1600.
60. Pérez-Carreras M., Del Hoyo P., Martín M.A., Rubio J.C., Martín A., Castellano G., et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003, 38:999-1007.
61. Vial G., Dubouchaud H., Couturier K., Cottet-Rousselle C., Taleux N., Athias A., et al. Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol 2011, 54:348-356.
62. Bansal S., Liu C.P., Sepuri N.B., Anandatheerthavarada H.K., Selvaraj V., Hoek J., et al. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J Biol Chem 2010, 285:24609-24619.
63. Schattenberg J.M., Wang Y., Singh R., Rigoli R.M., Czaja M.J. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signalling. J Biol Chem 2005, 280:9887-9894.
64. Kathirvel E., Morgan K., French S.W., Morgan T.R. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signalling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009, 21:973-983.
65. Begriche K., Massart J., Robin M.A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011, 54:773-794.
66. Moult P.J., Sherlock S. Halothane-related hepatitis. A clinical study of twenty-six cases. Q J Med 1975, 44:99-114.
67. Eghtesadi-Araghi P., Sohrabpour A., Vahedi H., Saberi-Firoozi M. Halothane hepatitis in Iran: a review of 59 cases. World J Gastroenterol 2008, 14:5322-5326.
68. Nguyen G.C., Sam J., Thuluvath P.J. Hepatitis C is a predictor of acute liver injury among hospitalisations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology 2008, 48:1336-1341.
69. Forget P., Wittebole X., Laterre P.F. Therapeutic dose of acetaminophen may induce fulminant hepatitis in the presence of risk factors: a report of two cases. Br J Anaesth 2009, 103:899-900.
70. Corcoran G.B., Wong B.K. Obesity as a risk factor in drug-induced organ injury: increased liver and kidney damage by acetaminophen in the obese overfed rat. J Pharmacol Exp Ther 1987, 241:921-927.
71. Kon K., Ikejima K., Okumura K., Arai K., Aoyama T., Watanabe S. Diabetic KK-Ay mice are highly susceptible to oxidative hepatocellular damage induced by acetaminophen. Am J Physiol Gastrointest Liver Physiol 2010, 299:G329-G337.
72. Blouin R.A., Dickson P., McNamara P.J., Cibull M., McClain C. Phenobarbital induction and acetaminophen hepatotoxicity: resistance in the obese Zucker rodent. J Pharmacol Exp Ther 1987, 243:565-570.
73. Ito Y., Abril E.R., Bethea N.W., McCuskey M.K., McCuskey R.S. Dietary steatotic liver attenuates acetaminophen hepatotoxicity in mice. Microcirculation 2006, 13:19-27.
74. Carmiel-Haggai M., Cederbaum A.I., Nieto N. Binge ethanol exposure increases liver injury in obese rats. Gastroenterology 2003, 125:1818-1833.
75. Robin M.A., Demeilliers C., Sutton A., Paradis V., Maisonneuve C., Dubois S., et al. Alcohol increases tumor necrosis factor alpha and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice. Hepatology 2005, 42:1280-1290.
76. Rutherford A., Davern T., Hay J.E., Murray N.G., Hassanein T., Lee W.M., et al. Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol 2006, 4:1544-1549.
77. Barshop N.J., Capparelli E.V., Sirlin C.B., Schwimmer J.B., Lavine J.E. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011, 52:198-202.
78. Abernethy D.R., Greenblatt D.J., Divoll M., Shader R.I. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983, 101:873-880.
79. Wong B.K., U.S.W., Corcoran G.B. An overfed rat model that reproduces acetaminophen disposition in obese humans. Drug Metab Dispos 1986, 14:674-679.
80. Bellentani S., Saccoccio G., Masutti F., Crocè L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
81. Biour M., Ben Salem C., Chazouillères O., Grangé J.D., Serfaty L., Poupon R. Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol Clin Biol 2004, 28:720-759.
82. Serviddio G., Bellanti F., Sastre J., Vendemiale G., Altomare E. Targeting mitochondria: a new promising approach for the treatment of liver diseases. Curr Med Chem 2010, 17:2325-2337.
83. Robin M.A., Anandatheerthavarada H.K., Biswas G., Sepuri N.B., Gordon D.M., Pain D., et al. Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J Biol Chem 2002, 277:40583-40593.